3/28/2013

A new compound drug could be effective in treating hepatitis C by attacking RNA that allows the virus to gain traction in a patient's body. The drug, miravirsen, targets the body's microRNA-122, preventing viral replication, according to findings published in the New England Journal of Medicine. The treatment could potentially also treat other serious diseases, including cancer. "This is really a revolution in science and it's now beginning to be translated into advances that control disease," said Phillip Sharp, an MIT molecular biologist who won a 1993 Nobel Prize for work on RNA.

Full Story:
Science News

Related Summaries